The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed implementation of nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over in line with NICE TA1077.
Note that the service that would provide nemolizumab for atopic dermatitis in adolescents (12 to 17 years) would be commissioned by NHS England
Nemolizumab for this indication will be considered as RED on the Joint Formulary with treatment initiation and continued prescribing by specialists in dermatology
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD.
This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
